Biogen Pharmachem Industries (531752) Q4 11/12 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 11/12 earnings summary
26 Oct, 2026Executive summary
FY12 revenue was ₹441,181 and net loss was ₹950,036, improving from a ₹1,533,814 loss in FY11; sluggish markets and financial stress weighed on operations.
Management said it was taking steps to strengthen operations and viability, and expected turnover to improve despite possible recessionary conditions.
Financial highlights
Total income fell to ₹441,181 from ₹656,931 YoY; FY12 income came from operations, while FY11 income was reported as other income.
Total expenditure declined to ₹1,391,217 from ₹2,190,754; PBT and net loss were both ₹950,036, versus ₹1,533,814 in FY11.
No tax expense or extraordinary items were recorded in FY12; no dividend was declared due to the loss.
Outlook and guidance
Management expected turnover to improve, citing strong fundamentals of Indian companies despite possible recessionary conditions in the industry.
Latest events from Biogen Pharmachem Industries
- Q2 returned to profit, while H1 revenue and net profit declined YoY.531752
Q2 26/27 - Revenue contracted sharply as profits narrowed; outlook centered on commodity trading and wind power.531752Q4 06/07
- FY08 trading contracted sharply, with conflicting reported profit figures and planned wind-power expansion.531752Q4 07/08
- Trading expanded, but a ₹43.33m loss and accumulated-loss risks overshadowed growth plans.531752Q4 08/09
- Net loss narrowed sharply, while preference warrants and corporate advances expanded the balance sheet.531752Q4 09/10
- Zero operating revenue and a wider FY2012-13 loss contrasted with a sharp rise in investments.531752Q4 12/13
- Nil operating revenue, a ₹1.30 million loss and sharply higher short-term borrowings marked FY14.531752Q4 13/14
- No operations, nil operating revenue, and a ₹1.33m FY15 net loss amid working-capital constraints.531752Q4 14/15
- Nil revenue and working-capital constraints kept operations inactive; FY15/16 net loss was ₹281,764.531752Q4 15/16